Tourette syndrome

Short-Term Study of Ecopipam Shows Reduction of Tics in Children with Tourette Syndrome

Retrieved on: 
Thursday, September 15, 2022
Tourette syndrome, University, Parkinsonism, Particle-size distribution, Safety, Incidence, Tremor, Department, Tic, MD, International Congress on Tuberculosis, Tic disorder, Aripiprazole, Hope, Movement disorders, Attention deficit hyperactivity disorder, Quality of life, Dopamine, Anxiety, Doctor of Philosophy, Associate, Disease, Neuron, Parkinson's disease, Depression, Pharmaceutical industry, TS

MILWAUKEE, Sept. 15, 2022 /PRNewswire-PRWeb/ -- A recent study evaluated the efficacy and safety of a pharmaceutical treatment, ecopipam, for children with Tourette syndrome (TS), according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Madrid, Spain. (Mahableshwarkar et al., 2022)

Key Points: 
  • MILWAUKEE, Sept. 15, 2022 /PRNewswire-PRWeb/ -- A recent study evaluated the efficacy and safety of a pharmaceutical treatment, ecopipam, for children with Tourette syndrome (TS), according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain.
  • Importantly, ecopipam is known for having a low incidence of adverse effects and was well-tolerated during the study.
  • The double-blind study lasted 12 weeks and examined children with Tourette's ranging from 6 to 17 years old.
  • Overall, this phase 2b study generates hope and supports that ecopipam deserves further investigation as a new treatment option for tics in TS."

SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Retrieved on: 
Wednesday, September 14, 2022
THC, Central nervous system, Warrant, Smith New Court Securities Ltd v Scrimgeour Vickers (Asset Management) Ltd, Asin, Advertising, TEL, Gel, Tourette syndrome, Beauty, U.S. Securities and Exchange Commission, CBD, Intention, Company, Acquisition, Growth, Private Securities Litigation Reform Act, Achievement, Hair, Status epilepticus, Exercise, Pain, ASIN, Annual report, Nasdaq, Autism, Candy, GLOBE, Marketing, SEC, Agitation, Alzheimer's disease, Pharmaceutical industry, Security (finance), Amazon

TEL AVIV, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) --   SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the signing of a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution™, a top- seller Amazon.com Marketplace (“Amazon”) account, American food supplements and cosmetics brand and trademark (the “Brand”). The Company has established a new wholly owned subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets.

Key Points: 
  • The Company has established a new wholly owned subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets.
  • Wellution offers eight variations of natural hemp candy supplements under two parent ASINs (Amazon Standard Identification Number) on Amazon that are differentiated by their hemp oil potency.
  • The leading parent ASIN, that was launched in 2019, has received over 26,500 reviews and is consistently ranked as the #1 best seller in the category.
  • In total, the Brand has over 40,000 product reviews, most of which are 4 and 5-star reviews.

Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study

Retrieved on: 
Tuesday, September 6, 2022
Trigeminal nerve, UCL, University College Hospital, Pain, Trigeminal neuralgia, Noema, Sofinnova, Glutamate (neurotransmitter), Seizure, Brain, LIBRA, Sensation, Diagnosis, Self-assessment, Pain scale, Neuropathic pain, GLOBE, Â, Nerve injury, Company, Diary, Tourette syndrome, Data collection, Face, PDE10A, Polaris Partners, CNS, UCLH, Tuberous sclerosis complex tumor suppressors, Patient, Basimglurant, Medical device, Pharmaceutical industry, Research, Biotechnology

BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).

Key Points: 
  • BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).
  • Thirty participants with a confirmed diagnosis of trigeminal neuralgia (TN) volunteered to complete the electronic diary.
  • While the analysis of the validation data is ongoing, the electronic diary was generally found to be easy to use and enabled participants to accurately describe the burden of trigeminal neuralgia (TN).
  • In addition to being patient friendly and easy to use, TNED is the first electronic diary designed specifically for people who suffer from TN.

DGAP-News: Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand

Retrieved on: 
Thursday, September 1, 2022
DGAP, Chronic pain, SE, EU, CEO, Pain, Research, Sleep, News, Anxiety, Flower, Prescription, Tourette syndrome, Depression, Synbiotics, Social Problems, Pharmacy, MS, Epilepsy, Gesellschaft mit beschränkter Haftung, Dronabinol, Eye, Marketing, Patient, Security (finance), Nightclub, Drug

Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58)

Key Points: 
  • Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58)
    In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair.
  • SynBiotic SE will present its new brand Hempamed Rx at its own booth.
  • In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH.
  • "With Hempamed Rx, we are not only focusing on a new strong brand for medical cannabis, we are also further expanding our sales team under the SynBiotic Sales umbrella."

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Retrieved on: 
Wednesday, August 24, 2022
CBD, Hebrew University of Jerusalem, THC, Eleazar Sukenik, CSE, Pain, OTC, Research, Central nervous system, MEAI, Risk, Status epilepticus, FSE, Tourette syndrome, SEC, Agitation, U.S. Securities and Exchange Commission, Addiction, Alzheimer's disease, Bar-Ilan University, Animal, GLOBE, Intention, Crave, TEL, Nasdaq, Company, Therapy, Cocaine, Gonda, Clinical trial, Annual report, Private Securities Litigation Reform Act, Acquisition, Autism, Rat, Pharmaceutical industry

TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

Key Points: 
  • "We are excited about these recent results in light of the potential synergistic effect between SciSparcs CannAmide and Clearminds MEAI, as previously demonstrated.
  • These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach, commented Oz Adler, SciSparc's Chief Executive Officer.
  • "These results reinforce our decision to enter a collaboration between the two companies."
  • Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.

Scisparc Announces the Full Exercise of Pre-Funded Warrants

Retrieved on: 
Friday, August 19, 2022
Company, TEL, Alzheimer's disease, Central nervous system, Exercise, THC, Nasdaq, Status epilepticus, Pain, Tourette syndrome, GLOBE, CBD, Autism, Agitation, Pharmaceutical industry

TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the full exercise of 3,211,100 pre-funded warrants that were issued as part of a private placement financing for gross proceeds of $10 million, which closed on June 1, 2022.

Key Points: 
  • TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (Company or SciSparc), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the full exercise of 3,211,100 pre-funded warrants that were issued as part of a private placement financing for gross proceeds of $10 million, which closed on June 1, 2022.
  • The full exercise of the 3,211,100 pre-funded warrants, which were exercised at a nominal exercise price of $0.001 per share, has resulted in the issuance of 3,211,100 ordinary shares.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • SciSparcs focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand

Retrieved on: 
Thursday, August 18, 2022
U.S. Securities and Exchange Commission, Documentation, Status epilepticus, Tourette syndrome, GLOBE, Good, Cobbe v Yeoman's Row Management Ltd, Private Securities Litigation Reform Act, SEC, Amazon (company), Cosmetics, THC, Annual report, Pain, Good manufacturing practice, Autism, Marketing, Agitation, Company, Acquisition, Alzheimer's disease, Central nervous system, GMP, CBD, LOI, Intention, Nasdaq, Advertising, TEL, Pharmaceutical industry

TEL AVIV, Israel, Aug. 18, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that following the signing of a non-binding letter of intent (“LOI”) with Merhavit M.R.M Holding and Management Ltd (“M.R.M”) to acquire from it its rights to purchase a top-seller Amazon.com account and American food supplements and cosmetics brand and trademark (the “Brand”), the Company signed additional agreements with respect to its intention to acquire the Brand. As an indication of its intention to negotiate and enter into a definitive acquisition agreement, SciSparc has agreed to transfer $1.0 million to an escrow agent.

Key Points: 
  • As an indication of its intention to negotiate and enter into a definitive acquisition agreement, SciSparc has agreed to transfer $1.0 million to an escrow agent.
  • In the event of signing a binding definitive agreement to purchase the Brand, the $1.0 million will be used as part of the overall amount to be paid by Scisparc.
  • The Brand offers dozens of GMP (Good Manufacturing Practice) manufactured hemp-based, U.S. made, top-ranked products, including various food supplements for different purposes and cosmetics.
  • The management services would be provided by a company for which SciSparcs Chief Executive Officer and director serves as a director.

Missouri Medical Cannabis Market Size, Share & Trends Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Alternative Medicine, Health, Natural Resources, Cannabis, Chronic pain, Industry, Pain, Growth, Cancer, Prevalence, Patient, COVID-19, Conditional sentence, Medical cannabis, Epilepsy, Oil, Headache, Consumer, Autism, PTSD, Arthritis, Tourette syndrome, Drug, Poultry

The "Missouri Medical Cannabis Market Size, Share & Trends Analysis Report by Product (Flower, Oils & Tinctures), by Application (Chronic Pain, Tourette's), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Missouri Medical Cannabis Market Size, Share & Trends Analysis Report by Product (Flower, Oils & Tinctures), by Application (Chronic Pain, Tourette's), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • In addition, since November 2018, Missouri has allowed the cultivation, processing, manufacturing, and distribution of medical cannabis.
  • Since then, a sharp rise has been witnessed in the sales of medical cannabis, thereby impelling the growth in the state.
  • Based on application, the chronic pain segment dominated the market in 2021 with a share of over 25.0% owing to a large patient pool.

$3.94 Bn Cannabis Packaging Markets - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Packaging, Natural Resources, Cannabis, Manufacturing, Industry, Cancer, F&B, Prevalence, Alzheimer's disease, COVID-19, Food, Epilepsy, Automation, CAGR, Post-traumatic stress disorder, Social media, Migraine, PTSD, Arthritis, Parkinson's disease, Tourette syndrome, Adoption, Pharmaceutical industry, Drug, Potash, Cannabis, Growth

The "Cannabis Packaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Packaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Cannabis is a psychoactive drug derived from the Cannabis sativa plant and used for medical as well as recreational purposes.
  • How has the global cannabis packaging market performed so far and how will it perform in the coming years?
  • What is the structure of the global cannabis packaging market and who are the key players?

Mexico Medical Cannabis Market Size, Share & Trends Report 2022-2030: Market is Projected to grow at a Staggering CAGR of 49% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Alternative Medicine, Health, Natural Resources, Cannabis, Flower, Parkinson's disease, Nausea, Mexican Health and Aging Study, Chronic pain, Industry, Population, Depression, Growth, Beijing International Studies University, COVID, Sale, GSK, Anxiety, Medical tourism, Research, Pain, Government, Perception, Patient, Quality of life, Epilepsy, CBG, Cannabis, Alzheimer's disease, Tax, Tourette syndrome, WHO, Time, Medicinal plants, Drug, Dentistry, Arthritis, CBD, Cancer

The "Mexico Medical Cannabis Market Size, Share & Trends Analysis Report by Product (Flowers, Oil & Tinctures), by Application (Cancer, Chronic Pain, Depression & Anxiety, Arthritis), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mexico Medical Cannabis Market Size, Share & Trends Analysis Report by Product (Flowers, Oil & Tinctures), by Application (Cancer, Chronic Pain, Depression & Anxiety, Arthritis), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Due to the high population density and a big patient pool, medical cannabis is likely to become one of the most profitable industries in Mexico in the coming years.
  • The legalization of medical cannabis has rendered it more easily available and has thus propelled the growth of the market.
  • The market is anticipated to witness steady growth over the forecast period as medical cannabis is being utilized to treat a growing number of chronic ailments.